Docoh
Loading...

ORGS Orgenesis

Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensedPOCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies.

Company profile

Ticker
ORGS
Exchange
CEO
Vered Caplan
Employees
Incorporated
Location
Fiscal year end
Former names
Business Outsourcing Service, Inc.
SEC CIK
Subsidiaries
Orgenesis Korea Co. Ltd. • Orgenesis Belgiuim SRL • Orgenesis Ltd. • Orgenesis Maryland Inc. • Orgenesis Switzerland Sarl • Orgenesis Biotech Israel Ltd. • Koligo Therapeutics Inc. ...
IRS number
980583166

ORGS stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

5 Aug 21
21 Oct 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Nov 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Orgenesis earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 28.91M 28.91M 28.91M 28.91M 28.91M 28.91M
Cash burn (monthly) 4.47M 5.77M (positive/no burn) (positive/no burn) 3.83M 5.94M
Cash used (since last report) 16.66M 21.51M n/a n/a 14.3M 22.15M
Cash remaining 12.25M 7.4M n/a n/a 14.61M 6.76M
Runway (months of cash) 2.7 1.3 n/a n/a 3.8 1.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
20 May 20 Sidransky David Common Stock Buy Acquire P Yes No 6.98 10 69.8 180
13 May 20 Sidransky David Common Stock Buy Acquire P Yes No 5.96 70 417.2 170
12 May 20 Sidransky David Common Stock Buy Acquire P Yes No 5.9 90 531 100
7 May 20 Sidransky David Common Stock Buy Acquire P Yes No 5.42 10 54.2 10

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

14.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 35 40 -12.5%
Opened positions 10 6 +66.7%
Closed positions 15 5 +200.0%
Increased positions 6 17 -64.7%
Reduced positions 15 8 +87.5%
13F shares
Current Prev Q Change
Total value 33.93M 66.74M -49.2%
Total shares 3.54M 5.28M -32.9%
Total puts 74K 0 NEW
Total calls 0 0
Total put/call ratio Infinity
Largest owners
Shares Value Change
Bergen Asset Management 1.35M $7.02M 0.0%
Vanguard 929.33K $4.71M -15.8%
Geode Capital Management 193.61K $981K -31.5%
Millennium Management 131.79K $668K +954.8%
BLK Blackrock 128.06K $650K -87.6%
Renaissance Technologies 113.6K $576K -58.2%
STT State Street 82.5K $418K -71.1%
Ergoteles 74.32K $377K NEW
Tibra Equities Europe 64K $324K NEW
SG Americas Securities 63.99K $324K NEW
Largest transactions
Shares Bought/sold Change
BLK Blackrock 128.06K -907.02K -87.6%
STT State Street 82.5K -202.94K -71.1%
Vanguard 929.33K -173.94K -15.8%
Renaissance Technologies 113.6K -158.35K -58.2%
NTRS Northern Trust 39.65K -151.17K -79.2%
WFC Wells Fargo & Co. 589 -144.01K -99.6%
Millennium Management 131.79K +119.3K +954.8%
Nuveen Asset Management 0 -89.55K EXIT
Geode Capital Management 193.61K -89.08K -31.5%
Ergoteles 74.32K +74.32K NEW

Financial report summary

?
Competition
Pfizer
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Additionally, AJVA, AJVE, antibody, Australian, awarded, call, Caplan, Celleska, country, decline, detection, discretionary, distinct, employee, feet, Freestanding, German, GmbH, immune, inception, inclusive, interrelated, Investigational, Issuer, leasehold, licence, licenced, manipulated, mechanism, mesenchymal, minimum, occupancy, preferential, Pty, refining, rent, rentable, Revacel, reviewed, SA, Savicell, simultaneously, square, standalone, sublease, sum, University, Vered, Written
Removed: CEO, consummated, generate, safety, wholly

Patents

APP
Utility
Three Dimensional Clusters of Transdifferentiated Cells, Compositions and Methods Thereof
10 Jun 21
The present disclosure provides compositions and methods for providing a cell replacement therapy to treat various diseases, including pancreatic diseases and diabetes.
APP
Utility
Prophylactic Protection Against Viral Infections, Particularly Hiv
20 May 21
An experiment has shown that ranpirnase is a microbicide.
GRANT
Utility
Transdifferentiated cell populations and methods of use thereof
13 Apr 21
Disclosed herein are methods for manufacturing transdifferentiated populations of non-pancreatic human insulin producing cells, and methods for enriching populations of non-pancreatic β-cells for cells comprising an enriched capacity for transcription factor-induced transdifferentiation into a pancreatic β-cell phenotype and function.
GRANT
Utility
Cell populations, methods of transdifferentiation and methods of use thereof
16 Mar 21
The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic β-cell lineage.
APP
Utility
Bioxomes Particles, Redoxomes, Method and Composition
25 Feb 21
Provided an artificial bioxome particle comprising a cell membrane component and designed to undergo fusion with a target cell, wherein said bioxome particle is engineered to carry a cargo comprising at least one predetermined active molecule; and wherein said cargo can be released into the target cell after the fusion of the bioxome particle with the target cell; and wherein the cell membrane component is derived from a selected cellular or extracellular source; methods of use of the particles; and processes for manufacturing thereof.